newsfilter
← Latest News
Business Wire·

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today